<?xml version="1.0" encoding="UTF-8"?>
<p>If a patient is receiving a cholinesterase inhibitor and/or memantine to treat AD, the dose needs to be stable for 1 month prior to study entry. Psychotropic and other medications will be permitted; valacyclovir has no significant drug–drug or drug–food interactions.
 <xref rid="R30" ref-type="bibr">30</xref> All medication changes during the trial will be documented using the National Alzheimer’s Coordinating Centre (NACC) rating form.
</p>
